ASH 2021: A Third Anti-Sars-Cov2 mRNA Dose Does Not Overcome the Pejorative Impact of Anti-CD20 Therapy and/or Low Immunoglobulin Level in CLL/Lymphoma Patients
This abstract from the American Society of Hematology Annual Meeting and Exposition (ASH 2021) reported analysis of retrospective data from 91 adult patients in France with lymphoma or chronic lymphocytic leukemia (CLL) who enrolled in a study of antibody responses, measured two or more weeks after receiving second or third doses of anti-SARS-Cov2 mRNA vaccines (Pfizer or Moderna).